|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000169032 |
Summary for MAP2K1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000169032 | Gene symbol | MAP2K1 |
| Gene name | mitogen-activated protein kinase kinase 1 | |
| HGNC | 6840 | |
| Entrez ID | 5604 | |
| Gene type | protein_coding | |
| Synonyms | MAP2K1|MEK1|MAPKK1 | |
| UniProtAcc | Q02750 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000169032 | MAP2K1 | DB02152 | K-252a | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB03115 | 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB05239 | Cobimetinib | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB06616 | Bosutinib | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB06892 | (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB07046 | 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB07101 | PD-0325901 | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB08130 | N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB08208 | 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB08911 | Trametinib | SmallMoleculeDrug |
| ENSG00000169032 | MAP2K1 | DB11689 | Selumetinib | SmallMoleculeDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
| ENSG00000169032 | MAP2K1 | DB05239 | Cobimetinib | SmallMoleculeDrug | Melanoma |
| ENSG00000169032 | MAP2K1 | DB06616 | Bosutinib | SmallMoleculeDrug | Chronic Myelogenous Leukemia (CML) |
| ENSG00000169032 | MAP2K1 | DB08911 | Trametinib | SmallMoleculeDrug | Non-Small Cell Lung Cancer,Melanoma,Melanoma,Treat Solid Tumors Anywhere in the Body,Thyroid Cancer |
Top |
Structure and expression level for MAP2K1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MAP2K1 | 2.55e+03 | -1.27e+00 | 2.58e-01 | -4.93e+00 | 8.13e-07 | 5.94e-06 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for MAP2K1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for MAP2K1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg08161449 | chr15:66387338 | CGI:chr15:66386557-66387625 | UTR,promoter,exon,gene body | 2.40e-01 | 3.77e-01 | -5.87e+00 | 4.42e-09 | 4.15e-08 | -1.37e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Top |
Exon skipping events with PSI in TCGA for MAP2K1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for MAP2K1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| ESCA | MAP2K1-001 | chr15_66448033_+ | 2.53e-01 | 1.36e-01 | 3.29e+00 | 1.00e-03 | 4.99e-02 | 1.17e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for MAP2K1 |
| TFs related to MAP2K1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CHOL | POU3F3 | MAP2K1 | 3.82e+00 | 9.82e-01 | 2.45e+00 | 1.85e-03 | Male-biased |
| CHOL | PRDM6 | MAP2K1 | 3.84e+00 | 9.81e-01 | 2.66e+00 | 4.05e-03 | Male-biased |
| CHOL | TBP | MAP2K1 | 3.90e+00 | 9.81e-01 | 2.76e+00 | 4.80e-03 | Male-biased |
| CHOL | ZNF225 | MAP2K1 | 4.13e+00 | 9.89e-01 | 2.76e+00 | 1.90e-03 | Male-biased |
| CHOL | ZNF235 | MAP2K1 | 4.06e+00 | 9.85e-01 | 2.92e+00 | 5.01e-03 | Male-biased |
| CHOL | ZNF25 | MAP2K1 | 3.79e+00 | 9.83e-01 | 2.25e+00 | 8.47e-04 | Male-biased |
| CHOL | ZNF287 | MAP2K1 | 4.12e+00 | 9.87e-01 | 2.87e+00 | 3.15e-03 | Male-biased |
| CHOL | ZNF418 | MAP2K1 | 4.41e+00 | 9.94e-01 | 2.09e+00 | 2.25e-05 | Male-biased |
| CHOL | ZNF487 | MAP2K1 | 3.90e+00 | 9.81e-01 | 2.78e+00 | 5.35e-03 | Male-biased |
| CHOL | ZNF98 | MAP2K1 | 3.96e+00 | 9.81e-01 | 2.89e+00 | 6.35e-03 | Male-biased |
| PAAD | AIRE | MAP2K1 | 4.53e+00 | 9.81e-01 | 3.74e+00 | 1.24e-02 | Male-biased |
| PAAD | IRF1 | MAP2K1 | 4.17e+00 | 9.84e-01 | 3.21e+00 | 4.99e-03 | Male-biased |
| PAAD | POU2F2 | MAP2K1 | 4.37e+00 | 9.83e-01 | 3.51e+00 | 8.85e-03 | Male-biased |
| PAAD | POU3F3 | MAP2K1 | 4.50e+00 | 9.90e-01 | 3.44e+00 | 3.16e-03 | Male-biased |
| PAAD | ZNF25 | MAP2K1 | 4.41e+00 | 9.90e-01 | 3.27e+00 | 2.10e-03 | Male-biased |
| PAAD | ZNF418 | MAP2K1 | 4.95e+00 | 9.95e-01 | 3.71e+00 | 1.29e-03 | Male-biased |
| SARC | POU3F3 | MAP2K1 | 4.42e+00 | 9.82e-01 | 3.85e+00 | 9.39e-03 | Male-biased |
| SARC | ZNF25 | MAP2K1 | 4.27e+00 | 9.80e-01 | 3.70e+00 | 9.33e-03 | Male-biased |
| SARC | ZNF418 | MAP2K1 | 4.97e+00 | 9.95e-01 | 4.10e+00 | 1.66e-03 | Male-biased |
| SKCM | POU3F3 | MAP2K1 | 4.07e+00 | 7.81e-03 | 5.14e+00 | 9.87e-01 | Female-biased |
| SKCM | ZNF25 | MAP2K1 | 3.93e+00 | 8.63e-03 | 4.96e+00 | 9.84e-01 | Female-biased |
| SKCM | ZNF418 | MAP2K1 | 4.07e+00 | 2.23e-03 | 5.54e+00 | 9.95e-01 | Female-biased |
| MAP2K1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for MAP2K1 |
| RBPs related to ES in MAP2K1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| UVM | NCL | exon_skip_122902 | 7.88e+00 | 5.48e-03 | 8.23e+00 | 9.87e-01 | Female-biased |
| THYM | ESRP2 | exon_skip_122906 | 6.24e+00 | 2.56e-03 | 6.68e+00 | 9.81e-01 | Female-biased |
| DLBC | MATR3 | exon_skip_122920 | 1.06e+01 | 9.92e-01 | 1.03e+01 | 7.17e-03 | Male-biased |
| CHOL | SNRNP70 | exon_skip_122906 | 7.92e+00 | 9.95e-03 | 8.33e+00 | 9.83e-01 | Female-biased |
| BRCA | MATR3 | exon_skip_122920 | 1.04e+01 | 9.91e-01 | 9.79e+00 | 7.39e-03 | Male-biased |
| ESCA | BRUNOL6 | exon_skip_122899 | 6.99e+00 | 9.82e-01 | 6.45e+00 | 4.98e-03 | Male-biased |
| MESO | MATR3 | exon_skip_122920 | 1.01e+01 | 5.87e-03 | 1.05e+01 | 9.93e-01 | Female-biased |
| PAAD | MATR3 | exon_skip_122920 | 1.02e+01 | 4.63e-03 | 1.06e+01 | 9.94e-01 | Female-biased |
| MAP2K1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11856842 | chr15:61754529:T:C | - | 0.117082773865256 | 0.0336269529726948 | LUSC | Female-baised eQTL |
| rs78494976 | chr15:61799319:T:C | - | 0.111252026115857 | 0.00816648459777432 | LGG | Female-baised eQTL |
| rs55927532 | chr15:61785021:T:G | - | 0.0907123925997505 | 0.0373143247005151 | LGG | Female-baised eQTL |
| rs59860209 | chr15:61785022:C:G | - | 0.0907123925997505 | 0.0373143247005151 | LGG | Female-baised eQTL |
| rs77763799 | chr15:61785869:G:A | - | 0.0872748490662413 | 0.0497249500149469 | LGG | Female-baised eQTL |
| rs76137417 | chr15:61785872:A:C | - | 0.0872748490662413 | 0.0497249500149469 | LGG | Female-baised eQTL |
| rs7161996 | chr15:66804855:C:G | - | 0.134640803832208 | 0.0028833563252592 | LUAD | Female-baised eQTL |
| rs4776858 | chr15:66947207:A:G | - | -0.0531316050949403 | 0.028589406073686 | LUAD | Female-baised eQTL |
| rs266390 | chr15:66947783:A:G | - | -0.0519268620331716 | 0.0360474300343674 | LUAD | Female-baised eQTL |
| rs8029328 | chr15:60274767:C:G | - | 0.0668323424427473 | 0.0457642071499069 | LUAD | Female-baised eQTL |
| rs7495307 | chr15:66859671:A:G | - | -0.0969339121219088 | 0.0493490415093005 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs1466867 | chr15:69107327:C:A | - | -0.0982890748239682 | 0.0335154306711486 | SARC | Male-baised eQTL |
| rs7183815 | chr15:75971826:C:T | - | 0.0690465976459402 | 0.0381355435405719 | LGG | Male-baised eQTL |
| rs335706 | chr15:75908490:C:T | - | 0.0674793928299812 | 0.0440672030453316 | LGG | Male-baised eQTL |
| rs71403522 | chr15:75915768:C:T | - | 0.0674793928299812 | 0.0440672030453316 | LGG | Male-baised eQTL |
| rs335697 | chr15:75918026:C:T | - | 0.0674793928299812 | 0.0440672030453316 | LGG | Male-baised eQTL |
| rs335711 | chr15:75892399:C:T | - | 0.0662270780113257 | 0.0483528091720106 | LGG | Male-baised eQTL |
| rs2469039 | chr15:75968742:G:A | - | -0.0677187563791347 | 0.0488972079311209 | LGG | Male-baised eQTL |
| rs985849 | chr15:75969652:C:T | - | -0.0677187563791347 | 0.0488972079311209 | LGG | Male-baised eQTL |
| rs72625744 | chr15:61389884:A:G | - | 0.0573843761161591 | 0.00595868566716938 | KIRC | Male-baised eQTL |
| rs12439928 | chr15:61390254:A:C | - | 0.0529878606076559 | 0.0154822298986064 | KIRC | Male-baised eQTL |
| rs78417725 | chr15:61390668:C:T | - | 0.05213981668096 | 0.0189642179895226 | KIRC | Male-baised eQTL |
| rs8038664 | chr15:61390735:A:G | - | 0.05213981668096 | 0.0189642179895226 | KIRC | Male-baised eQTL |
| rs7162913 | chr15:61391843:A:G | - | 0.0515193135135653 | 0.0206683425133603 | KIRC | Male-baised eQTL |
| rs7163299 | chr15:61392006:A:T | - | 0.0507128665613823 | 0.0219170558368917 | KIRC | Male-baised eQTL |
| rs28721869 | chr15:65314378:T:C | - | 0.0548060137277891 | 0.0256937597575079 | BLCA | Male-baised eQTL |
| rs949592 | chr15:69123961:G:T | - | -0.0857940985891328 | 0.0263426754316796 | BLCA | Male-baised eQTL |
| rs2899823 | chr15:73813670:G:A | - | -0.085396426898109 | 0.0263442144629425 | BLCA | Male-baised eQTL |
| rs74724610 | chr15:69125379:A:G | - | -0.085744509996253 | 0.0263925471548516 | BLCA | Male-baised eQTL |
| rs535406 | chr15:58417564:T:A | - | -0.091242726306183 | 0.0432981932577044 | BLCA | Male-baised eQTL |
| rs1372833 | chr15:65340714:C:T | - | 0.0538611119177441 | 0.046933358128357 | BLCA | Male-baised eQTL |
| rs58254794 | chr15:64849087:C:T | - | 0.0668961062992435 | 0.0238630600904422 | COAD | Male-baised eQTL |
| rs4776637 | chr15:64853610:A:C | - | 0.0667877738395491 | 0.0238907330968079 | COAD | Male-baised eQTL |
| rs4776249 | chr15:64853612:C:G | - | 0.0667877738395491 | 0.0238907330968079 | COAD | Male-baised eQTL |
| rs35646705 | chr15:64854283:C:T | - | 0.0667877738395491 | 0.0238907330968079 | COAD | Male-baised eQTL |
| rs1107529 | chr15:64857730:C:T | - | 0.0665992597122062 | 0.0243453541278172 | COAD | Male-baised eQTL |
| rs12439917 | chr15:64870575:G:A | - | 0.0626193979222587 | 0.036184093903594 | COAD | Male-baised eQTL |
| rs11072213 | chr15:70675215:G:T | - | -0.057462519451799 | 0.03940916029395 | COAD | Male-baised eQTL |
| rs1719263 | chr15:64883993:G:T | - | 0.0629846458967893 | 0.0394120757473296 | COAD | Male-baised eQTL |
| rs1684032 | chr15:64893685:G:T | - | 0.0605029003221691 | 0.0454397085010369 | COAD | Male-baised eQTL |
| rs1719262 | chr15:64893705:T:A | - | 0.0605029003221691 | 0.0454397085010369 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000169032 |
| CpG Site: cg08120210 | |
| Position to Gene: gene,enhancer | |
| Male Effect: - | |
| Female Effect: -0.20179256731087 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg08120210 | chr15:66390395 | gene,enhancer | -0.20179256731087 | 1.63294571333304e-07 | -0.410373402144483 | 1.8817602770763778e-11 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of MAP2K1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000169032 | MAP2K1 | C0007786 | Brain Ischemia | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C0023443 | Hairy Cell Leukemia | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C0025202 | melanoma | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C0028326 | Noonan Syndrome | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C0041409 | Turner Syndrome, Male | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C0041696 | Unipolar Depression | 1 | PSYGENET |
| ENSG00000169032 | MAP2K1 | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C0587248 | Costello syndrome (disorder) | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C0917798 | Cerebral Ischemia | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C1269683 | Major Depressive Disorder | 1 | PSYGENET |
| ENSG00000169032 | MAP2K1 | C1275081 | Cardio-facio-cutaneous syndrome | 2 | CTD_human |
| ENSG00000169032 | MAP2K1 | C1527404 | Female Pseudo-Turner Syndrome | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C2063866 | Depressive Disorder, Treatment-Resistant | 1 | PSYGENET |
| ENSG00000169032 | MAP2K1 | C2931456 | Prostate cancer, familial | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C4551602 | Noonan Syndrome 1 | 1 | CTD_human |
| ENSG00000169032 | MAP2K1 | C4722327 | PROSTATE CANCER, HEREDITARY, 1 | 1 | CTD_human |
